Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19)
Clinical trial NCT05007951 · COMPLETED
Trial details
- NCT number
- NCT05007951
- Sponsor
- SK Bioscience Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-30
- Primary completion
- 2023-10-02
- Enrollment
- 4036
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.